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Prognostic factor research aims to identify factors associated with
subsequent clinical outcome in people with a particular disease or health
condition. In this article, the second in the PROGRESS series, the
authors discuss the role of prognostic factors in current clinical practice,
randomised trials, and developing new interventions, and explain why
and how prognostic factor research should be improved.
A prognostic factor is any measure that, among people with a
given health condition (that is, a startpoint), is associated with a
subsequent clinical outcome (an endpoint). For example, in many
cancers tumour grade at the time of histological diagnosis is a
prognostic factor because it is associated with time to disease
recurrence or death. This is illustrated in Figure 1, which shows
that in 246 patients with breast cancer treated with tamoxifen the
survival times were shorter in those with a higher tumour grade
status [1]. Prognostic factors thus distinguish groups of people with
a different average prognosis and thus inform and enhance the
basic prognosis summaries that were discussed for outcomes
research in paper 1 of our series [2].
In many diseases, the most researched prognostic factors are
biomarkers [3]. Biomarkers include a diverse range of biological
(including genomic [4], transcriptomic [5], proteomic, metabo-
lomic), pathological, imaging, clinical, and physiological variables:
for example, in children with neuroblastoma, elevated expression
of the MYCN oncogene is associated with a shorter time to
recurrence and death [6]. Symptoms and behavioural and
psychosocial characteristics may also be prognostic: for example,
in patients with low back pain, psychosocial factors such as
maladaptive pain coping and comorbid depression and higher
levels of functional limitation at clinical presentation have been
shown to be associated with worse outcomes [7].
Prognostic factors may also be measured outside the individual,
at an ecological level (in which the exposure of individuals is
inferred), such as area-level social deprivation, healthcare access
and quality, and physical environment. For example, mortality
and morbidity rates in UK patients with coronary heart disease
vary by socioeconomic group (rates are higher in lower
socioeconomic groups) and by geographical area (rates are highest
in Wales, North West England, and the Northern England and
Yorkshire regions and lowest in South East England) [8].
Prognostic factor research aims to discover and evaluate factors
that might be useful as modifiable targets for interventions to
improve outcomes, building blocks for prognostic models, or
predictors of differential treatment response. Prognostic factor
The Guidelines and Guidance section contains advice on conducting and
reporting medical research.
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research is found extensively in the medical literature, with
thousands of studies published each year [9]. Genuine prognostic
factors can play an important role in many of the pathways
towards improved clinical outcomes (see pathways schema at the
bottom of Figure 2, introduced in paper 1 in our PROGRESS
series [2]). The first aim of this article is to illustrate the broad
potential of identifying prognostic factors, from their use within
current clinical practice to their implications for randomised trial
design and developing new interventions. The second aim is to
highlight why the overall quality of prognostic factor research is
currently poor [3] [10–12] and to make recommendations for
improving the reliability of the accumulated prognostic factor
evidence over time in order to ensure identification of factors that
can be used to influence practice.
Importance of Prognostic Factors for Current
Clinical Practice
Evidence from prognostic factor research has a broad array of
uses in healthcare and clinical research. We start by considering
how they are currently used to influence clinical decision making.
Changing How Diseases and Health Conditions Are
Defined
A fundamental role of prognostic factors is to aid the definition
of a disease or health condition [13], to inform or refine diagnosis,
and to enhance average prognosis summaries [2]. For example,
diagnosis of cancer is usually accompanied by the stage of disease,
which is based on the prognostic factors of tumour size, nodal
status, and metastasis. Another example is CD4 cell count; this was
not initially included in the definition of AIDS, but evidence that it
was a strong prognostic factor (associated with a range of measures
of disease progression) and understanding of its biological
significance led to its inclusion in diagnostic criteria. Future
developments are anticipated from the use of genomics to discover
Summary Points
N The PROGRESS series (http://www.progress-partnership.
org) sets out a framework of four interlinked prognosis
research themes and provides examples from several
disease fields to show why evidence from prognosis
research is crucial to inform all points in the translation
of biomedical and health related research into better
patient outcomes. Recommendations are made in each
of the four papers to improve current research
standards.
N What is prognosis research? Prognosis research seeks to
understand and improve future outcomes in people with
a given disease or health condition. However, there is
increasing evidence that prognosis research standards
need to be improved.
N Why is prognosis research important? More people now
live with disease and conditions that impair health than
at any other time in history; prognosis research provides
crucial evidence for translating findings from the
laboratory to humans, and from clinical research to
clinical practice.
N A prognostic factor is any measure that, among people
with a given startpoint (such as diagnosis of disease), is
associated with a subsequent endpoint (such as death).
N Prognostic factors have many potential uses: for
example, they help define disease at diagnosis, inform
clinical and therapeutic decisions (either directly or as
part of prognostic models for individualised risk
prediction), enhance the design and analysis of inter-
vention trials, and help identify targets for new
interventions that aim to modify the course of a disease
or health condition.
N Limitations in current prognostic factor research include
publication bias, reporting biases, poor statistical anal-
yses, and inadequate replication of initial findings.
N To address these issues we recommend that large,
prospective, registered, and protocol supported prog-
nostic factor studies are needed with suitable sample
size, appropriate statistical analyses, and transparent
reporting of all factors and outcomes considered. Initial
exploratory studies are also important, but must be
labelled as such.
N A factor’s prognostic ability should be examined across
multiple studies, and we recommend increased use of
(ideally prospectively planned) meta-analysis of individ-
ual participant data, as it potentially alleviates any
reporting biases and analysis deficiencies in primary
studies.
N For each factor identified as prognostic, there should be
greater understanding of how it can be used to improve
clinical outcomes, including whether it is useful within
the clinical management of patients and whether it
informs the development of novel interventions.
N The other papers in the series are:
# PROGRESS 1: BMJ 2013, doi:10.1136/bmj.e5595
# PROGRESS 3: PLOS Med 2013, doi:10.1371/journal.
pmed.1001381
# PROGRESS 4: BMJ 2013, doi:10.1136/bmj.e5793
Figure 1. Tumour grade as a prognostic factor in breast cancer.
Kaplan-Meier curves for disease-free survival for three groups of breast cancer
patients defined by tumour grade status (1, 2, or 3). Curves are derived from
246 breast cancer patients treated with tamoxifen who had 94 recurrences or
deaths over a possible 7 years of follow-up (reproduced with published data
relating to Schumacher et al [1]). The distinct curves, significant log rank result,
and hazard ratio estimates suggests tumour grade is a prognostic factor, as it
identifies three groups of patients with a different average prognosis.
doi:10.1371/journal.pmed.1001380.g001
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new ‘‘classes’’ of disease, and prognosis research is evaluating gene
expression signatures [14].
Informing Treatment Recommendations and Individual
Patient Management
Randomised controlled trials are the main study design for
informing treatment decisions. However evidence on individual
prognostic factors may be used to further inform treatment choices.
For example, the use of drug eluting stents for the treatment of
coronary artery disease was restricted by the National Institute for
Health and Clinical Excellence (NICE) to patients with coronary
artery lesions longer than 15 mm, a prognostic factor for the
probability of restenosis [8]. Patients with such lesions had a worse
prognosis and thus were considered to have a greater potential to
gain from receiving drug eluting stents than patients without it.
The identification of new prognostic factors may also widen the
criteria for patients suitable for treatment. For example, a recent
study of women undergoing sentinel node biopsy for breast cancer
indicates that, even after adjustment for established prognostic factors
(age, tumour size, tumour grade, and hormone receptor status), the
presence of isolated tumour cells is associated with a higher rate of
recurrence and death, and is thus a prognostic factor [15]. The
American Joint Committee on Cancer currently defines patients with
isolated tumour cells as ‘‘node negative’’; the authors of this study
conclude that this should be re-evaluated, potentially expanding the
group of patients in whom adjuvant therapy is currently given [15].
Building Blocks for Prognostic Models
Individual risk prediction is usually poor when based on just one
factor. To improve the targeting of interventions to patients based on
their predicted individual risk of subsequent outcomes, decision
makers can use multiple prognostic factors combined within a
prognostic model. For example, a prognostic model developed to
help identify patients with traumatic brain injury who are likely to
have an unfavourable sixmonth outcome [16] involves the prognostic
factors of age, motor score, pupillary reactivity, computed tomo-
graphic characteristics, and laboratory parameters. Some prognostic
models for predicting individual outcome risk are being used in
clinical practice, such as the GRACE score in acute myocardial
infarction or the ADJUVANT! score in breast and other cancers, and
we consider them further in the third paper in our series [17].
Potential Predictors Of Treatment Response for Stratified
Medicine
The current drive toward stratified medicine requires the
identification of factors associated with more benefit or less harm
from a specific treatment [18]. Prognostic factors (or prognostic
models for individual risk prediction based on multiple prognostic
factors) are natural variables to consider for this role; not only do they
identify those at highest risk, who generally benefit most, but they
may even predict treatment response. An example of a prognostic
factor that also predicts treatment response is epidermal growth factor
receptor tyrosine kinase (EGFR-TK) status in non-small cell lung
cancer. NICE has recommended use of gefitinib as first line treatment
for this disease only in those patients who tested positive for EGFR-
TK [19]. We note, though, that only a few prognostic factors will also
be predictive of differential treatment response [20]. We return to
stratified medicine in our fourth PROGRESS paper [21].
Use for Monitoring Disease Progression
Clinicians use prognostic factors to monitor changes in disease
status and treatment response over time [22]. For example,
Figure 2. Evaluation of whether homocysteine is a prognostic factor, and whether modifying it improves clinical outcome in
patients with coronary disease (drawn from data in [35]). Path element adapted from Chart 7.1 in the Cooksey report (2006) http://bit.ly/
Ro27rL (made available for use and re-use through the Open Government License).
doi:10.1371/journal.pmed.1001380.g002
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measurement of haemoglobin A1c (HbA1c) levels in people with
diabetes [23] allows clinicians, with one blood test, to assess the
average serum glucose values over the previous 120 days and to
make inferences about how well interventions have controlled
glucose levels. Evidence that HbA1c is a prognostic factor (strongly
associated with the risk of subsequent vascular events) influenced
guideline recommendations that it should be routinely assessed
[24]. Other examples of prognostic factors being used for
monitoring include CD4 count in HIV infection, blood pressure
or temperature in critical care medicine, and carcinoembryonic
antigen (CEA) levels in colorectal cancer [25].
Importance of Prognostic Factors for Intervention
Research and Trials
Alongside their usefulness in clinical practice, prognostic factors
also inform and facilitate intervention research.
Development of New Interventions to Modify a
Prognostic Factor
Prognostic factors may suggest the development of new
interventions, or new applications of existing interventions, under
the assumption of a causal relationship between the factor and
subsequent outcome. A causal factor is prognostic because it
directly or indirectly causes future outcomes, and so modifying a
causal prognostic factor will change the average disease course. An
example of a prognostic factor that has subsequently informed
intervention strategies in the management of low back pain is the
psychological behavioural factor ‘‘fear avoidance beliefs.’’ This
factor describes exaggerated pain perceptions and fear of
experiencing pain leading to avoidance of activities that are
perceived to cause pain. Evidence supporting an association
between fear avoidance beliefs during an acute episode of low back
pain and subsequent chronic disability includes several prospective
cohort studies, synthesised in systematic reviews [26,27]. Clinicians
and researchers have hypothesised that fear avoidance beliefs may
be a modifiable prognostic factor and have recommended patient
management to decrease fear avoidance and promote normal
activities (such as through graded activity exposure) [28,29]. A
randomised controlled trial in primary care evaluated use of fear
reducing and activating techniques and found a decrease in
disability related to low back pain [30]. There are many other
examples of prognostic factors hypothesised to be modifiable and
which could stimulate new interventions targeted to modify them.
For example, mild anaemia is prognostic in stable coronary artery
disease [31], and blood glucose measured at admission is
prognostic in traumatic brain injury [32,33].
It should never be assumed that intervening on a prognostic
factor will improve outcome. Before embarking on a randomised
trial to evaluate the benefit of modifying a prognostic factor, it is
important to recognise that most prognostic factors will not be
causal and are merely associated with the true (often unknown)
causal factors. Indeed, as in aetiological research, it is difficult to
establish whether a particular factor is truly causal, and one must
consider multiple sources of evidence from high quality studies [34].
For example, is there repeated confirmation (from multiple studies)
that the factor is prognostic? Does the factor retain prognostic value
even after adjustment for other prognostic factors? Is there evidence
of how the factor fits on the (causal) pathway from disease to
outcome, and an understanding of the biological mechanism
involved? Do randomised trials of interventions that modify the
prognostic factor provide evidence of improved outcome?
The example of homocysteine in coronary artery disease
illustrates the issues of modification and causality of a prognostic
factor (Figure 2) and the role of three different study designs [35].
A meta-analysis of 16 observational cohort studies suggested that,
after adjustment for other prognostic factors (confounders), lower
homocysteine levels are associated with a better prognosis in terms
of coronary death and non-fatal myocardial infarction. This
evidence is concordant with that from a meta-analysis of 80
genetic studies that used a Mendelian randomisation design (where
the variants associated with homocysteine were randomly allocat-
ed at conception) to adjust for confounders. These two study
designs suggest that homocysteine is a prognostic factor and
provide a rationale for experimental studies lowering homocyste-
ine. However, a meta-analysis of seven randomised trials of folate
supplementation, which is known to lower homocysteine, did not
show any benefit in terms of improved patient outcome. This trial
evidence is consistent with different interpretations, including that
homocysteine is not causal (as modifying it did not improve
outcome) and that homocysteine is causal but the lack of
reversibility was due to the particular intervention used. Thus,
even in situations with a large evidence base of how modifying the
factor changes outcome, inferences that a prognostic factor is
causal are problematic and should be treated with caution.
Aiding Design and Analysis of Intervention Studies
Prognostic factors can be important in the design and analysis of
intervention studies, including randomised trials [36] where
stratified randomisation (or minimisation) may be used to ensure
treatment groups are balanced across levels of a prognostic factor.
If prognostic factor values are not balanced across treatment
groups of interest then they may mask the true effect of an
intervention on disease outcome. In other words, prognostic
factors are potential confounding factors, and so in cohort studies
or trials with unbalanced treatment groups it may be desirable to
adjust for them in the statistical analysis to limit or reduce potential
confounding. For example, Royston et al show how adjustment
(within a statistical model) for an established prognostic factor in
randomised trials with baseline imbalance can change the
inference about treatment effectiveness [37]. Even in randomised
trials or genome-wide studies with no baseline imbalance,
statistical analyses may adjust for prognostic factors to gain power
[38–40].
Prognostic Factor Research: From Discovery to
Replication
Given these broad potential uses of prognostic factors, high
quality research to identify prognostic factors is essential. To this
end, different phases of such research have been noted [34,41].
Broadly, prognostic factor evidence should evolve from initial
studies that aim to identify or explore factors about which little if
anything is known in relation to prognosis (exploration), to studies
that seek to evaluate previously identified prognostic factors and to
assess their prognostic value over established prognostic factors
(replication and confirmation). We now explain these components
in more detail.
Exploration
Approaches to identify possible potential prognostic factors
usually incorporate biological reasoning (‘‘candidate’’ approach)
and the hypothesised causal pathway from the onset of disease or
condition to subsequent outcome. Although there are few, if any,
conditions for which there is no information on prognostic factors,
there is a growing role for hypothesis-free (‘‘biology agnostic’’)
studies to discover previously unsuspected factors. Such studies do
not focus on one (or a few) specific prognostic factors, but rather
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investigate many factors (for example, 10–20 psychosocial factors
or millions of genetic variants) and their association with outcome.
Although sometimes overlooked, simple clinical information and
factors used to diagnose a disease or health condition may be used
in exploration. The availability of new analytical technologies has
supported recent rapid growth in the use of ‘‘omic’’ [42,43]
approaches to discover potential prognostic factors using DNA
(genomics), RNA (expression products, transcriptomics) [5],
proteins (proteomics), or metabolites (metabolomics).
Replication and Confirmation
Once potential prognostic factors have been identified in one
study, early replication in multiple independent studies is
important, together with assessment of prognostic value over
other factors. For example, a meta-analysis of individual partic-
ipant data from six studies in traumatic brain injury showed that
blood glucose has incremental prognostic value over established
prognostic factors of age, motor score, and pupillary reactivity in
relation to a poor outcome (a Glasgow outcome score of 1–3 at 6
months) (see Figure S1) [33].
Illustrative Example
The standard of research that has emerged in genome-wide
association studies is that discovery and multiple replication are
combined in the first publication (illustrated in Figure 3). An
exploratory study, with no prior hypotheses about which genes
would be prognostic, identified an association between a variant in
the gene called OCA2 with survival among women with oestrogen
receptor negative breast cancer; 15 additional studies were then
synthesised immediately and successfully replicated this association
[4]. An implication of this finding for clinical research is that,
because of the biology of OCA2, this prognostic factor should be
tested as a candidate for predicting differential treatment response
to anthracycline drugs.
Prognostic Factor Research: Recommendations
for Improvement
Given the abundance of prognostic factor research, it is
surprising that the methodology regarding the design, conduct,
and analysis of prognostic factor studies is not well established
[34,41,44–47]. Further, an increasing body of evidence has
highlighted severe limitations [3,10–12]. The studies are often
poorly designed [41,45], inappropriately analysed [44,48], and
poorly reported [28,49,50]. For example, in a review of prognostic
factor studies in paediatric oncology, prognostic effect sizes (such
as hazard ratios) and their confidence intervals could be extracted
for only 35.5% of the prognostic factor assessments reported [51].
Replication of initial prognostic factor evidence is also poor. For
example, a review of prognostic factors in neuroblastoma found
that 130 different genetic and biological factors had been
investigated in 211 published studies, with a median of one
publication per factor. Publication bias and selective reporting of
primary studies seems endemic [52]. For example, Kyzas et al
evaluated 1575 articles on different prognostic factors for cancer,
and staggeringly found that nearly all suggested significant
findings, with 98.5% reporting statistically significant results or
elaborating on non-significant trends [52].
These problems often result in confusion about the prognostic
value of individual factors [12], and consequently genuine
prognostic factors have a smaller impact than they ought to have
on improving health outcomes. Box 1 illustrates, across a wide
variety of clinical fields, the frustration of those attempting to
conduct and draw inferences from systematic reviews and meta-
analyses of published prognostic factor studies [4,11,53–60].
Clearly standards must be raised. Many of the recommendations
highlighted across the PROGRESS series (see Table S1) are
relevant. Here we make recommendations within five priority
areas. Many of these are also relevant for the other types of
prognosis research considered in our series.
Planning, Design, and Analysis
Researchers and funders should develop a clearer understand-
ing of the progression of research evidence about prognostic
factors: from initial discovery, through to replicable evidence of
prognostic ability, and application (or being discarded, if
appropriate) (recommendation 9 in Table S1). Study objectives
should be presented in the context of existing evidence. Guidelines
for those planning and undertaking a prognostic factor study have
been suggested [3,41,45] and should be used to ensure higher
standards of study quality, design, and analysis than is currently
observed and to emulate the standards set by randomised trials
(recommendation 10) [61]. These should include the need for
study registration, a published protocol, ideally a prospective
approach, and an appropriate statistical analysis plan.
Registration of protocols in a publically accessible register (such
as clinicaltrials.gov) would make others aware of ongoing research,
encourage the pre-specification of objectives and factors of
interest, and reduce publication and selective reporting biases
(recommendations 11 and 12). A prospective rather than
retrospective design is preferable (recommendation 10) as it
enables clear inclusion criteria, more complete baseline and
follow-up data, and greater standardisation of diagnostic and
therapeutic procedures, and ensures the primary factors and
outcomes are specified in advance, reducing the potential for data
dredging and thus type I errors. This is especially important for
larger studies aiming to replicate earlier exploratory prognostic
factor findings, and these should incorporate a suitable sample size
calculation to ensure adequate power to detect a prognostic effect,
if it exists. Statistical analysis methods can be substantially
improved [44] by analysing continuous factors on their continuous
scale, thereby avoiding the use of arbitrary cut-points to categorise
them [48], by considering non-linear relationships, and by
including multivariable analyses that assess a factor’s prognostic
value over existing prognostic factors [44] (recommendation 13).
For many diseases and health conditions there is a lack of
clinical cohorts to evaluate prognostic factors appropriately. New
clinical cohorts should be established in which consenting
individuals with specified health related condition(s) (including
diagnosed disease, and symptoms) are phenotyped and have
multiple baseline characteristics measured, are placed within a
biorepository (if appropriate), and are followed up with their
multiple health outcomes recorded (and linked to and from other
databases as necessary). Research funders should help establish
new investigator-led clinical cohorts that meet the criteria which
we set out; currently healthy population cohorts tend to
predominate (recommendation 14).
Nomenclature and Quality of Reporting
Prognostic factor studies must also improve their transparency
of reporting [49] in order to help promote new prognostic factors,
resolve ongoing debate over the prognostic value of existing
factors, distinguish good quality research from low quality
research, facilitate systematic reviews and meta-analyses in the
subject [46,62], and ultimately help decision makers use prognos-
tic factor evidence (recommendation 15). The REMARK report-
ing guidelines [63] provide recommendations for prognostic factor
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studies in oncology, but most of these recommendations are
generalisable to non-cancer diseases.
Another barrier to interpreting prognostic factor research is the
inconsistent nomenclature used both within and across disease
specialties. For example, prognostic factors are alternatively
known as prognostic variables, prognostic (bio)markers, prognostic
indicators, prognostic determinants, predictors, or molecular
markers, among others. Prognosis research publications should
use standard terms and nomenclature in order for different
laboratory, clinic, and population disciplines to interact, and for
research findings to be interpreted appropriately and consistently
by clinicians and patients (recommendation 16).
Figure 3. Discovery of prognostic factors: a genome-wide association study of survival among people with breast cancer, and
replication in 15 studies (Mid-figure forest plot based on example plots in [4]. Path element adapted from Chart 7.1 in the Cooksey report
(2006) http://bit.ly/Ro27rL (made available for use and re-use through the Open Government License).
doi:10.1371/journal.pmed.1001380.g003
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Replication, Data Sharing, and Evidence Synthesis
As there is a need for initial evidence of a prognostic factor to be
shown as consistent in subsequent studies, researchers must support
systematic reviews and evidence synthesis of prognostic factor
studies. In particular, we strongly support calls for authors to
facilitate meta-analysis of individual participant data from prog-
nostic factor studies through data sharing initiatives (recommenda-
tion 17) [3,49]. Such an analysis uses original source data at the
participant level and has many advantages over a meta-analysis of
summary results from the literature [64]. In particular, one can
derive desired prognostic factor results directly, independent of
study reporting and significance, and analyse continuous factors
more appropriately [37]. Meta-analyses of individual participant
data are achievable for prognostic factors: for example, collabora-
tors united to provide individual participant data from 11 studies of
traumatic brain injury to form a prognostic factor database
including 9205 patients [32]. This should be encouraged in other
specialties, and ideally meta-analyses of individual participant data
should be prospectively planned [3] (a design used for over a decade
in epidemiology [65]) to minimise heterogeneity between studies
(such as in factors assessed, methods of measurement, and inclusion
criteria) and unavailability of data [66].
Impact of Research Findings
Prognostic factor studies need to improve in providing a clear
message about the implications of their findings for clinical
practice, randomised trials, or further research. For example,
prognosis researchers should consider if further research is needed
to confirm that a factor has prognostic value. If there is consistent
evidence of prognostic value, then what are the potential uses of
the prognostic factor within healthcare research and clinical
decision making? Are there any implications for the use of known,
or the development of novel, interventions? Such considerations
should be made in order to help move prognostic factor research
findings into the different translational pathways toward improv-
ing clinical outcomes (recommendation 18).
Many of the uses of prognostic factors—such as informing
diagnosis, tailoring treatment decisions, and monitoring patients—
constitute a health technology for clinical practice. However, the
potential impact of implementing prognostic factors—in terms of
costs, outcomes, and broader healthcare impacts—are rarely
evaluated (unlike with drugs and interventions), and this should be
addressed (recommendation 19). Indeed, the nature and extent of
evidence required to do this must also be clarified. This echoes
recent calls for randomised trials [67] or decision modelling
techniques [24,68] to investigate the added value of prognostic
factors in clinical practice.
Conclusion
Prognostic factors have the potential to play an important role
in pathways towards improved health, including clinical practice,
healthcare research, and the development, evaluation, and
targeting of interventions. Improvements in the design, conduct,
analysis, and reporting of prognostic factor research are crucial to
enable more reliable prognostic factor evidence that can be used in
these pathways and ultimately help improve patient outcomes.
Supporting Information
Figure S1 Blood glucose as a prognostic factor in
traumatic brain injury (drawn using data from
[32,33]). The forest plots shows two random-effects meta-analyses
of individual participant data from 6 studies, aiming to establish
Box 1. Evidence from systematic reviews and
overviews indicating that the quality of
prognostic factor research needs to improve
General ‘‘As a consequence of the poor quality of
research, prognostic markers may remain under investiga-
tion for many years after initial studies without any
resolution of the uncertainty. Multiple separate and
uncoordinated studies may actually delay the process of
defining the role of prognostic markers’’ [53]
‘‘The (prognostic factor) literature is probably cluttered
with false-positive studies that would not have been
submitted or published if the results had come out
differently’’ [11]
Bladder cancer ‘‘After 10 years of research, evidence is
not sufficient to conclude whether changes in P53 act as
markers of outcome in patients with bladder cancer….
That a decade of research on P53 and bladder cancer has
not placed us in a better position to draw conclusions
relevant to the clinical management of patients is
frustrating’’ [54]
Coronary disease ‘‘Multiple types of reporting bias, and
publication bias, make the magnitude of any independent
association between CRP and prognosis among patients
with stable coronary disease sufficiently uncertain that no
clinical practice recommendations can be made’’ [55]
Musculoskeletal disorders: low back pain ‘‘We
observed the potential impact of different methods on
the results of systematic reviews in the area of low back
pain prognosis. This emphasizes the need for cautious
interpretation and careful attention to methods and
transparent reporting in future reviews. There is an
immediate need for methodological work in the area of
prognosis systematic reviews to investigate potential
biases’’ [60]
Acute orthopaedic trauma ‘‘There was limited evidence
for the role of any factor as a predictor of return to work.…
Due to the lack of factors considered in more than one
cohort, the results of this review are inconclusive. The
review highlights the need for more prospective studies
that are methodologically rigorous, have larger sample
sizes and consider a comprehensive range of factors’’ [56]
Whiplash ‘‘Data regarding the prognostic factors associ-
ated with poor recovery were difficult to interpret due to
heterogeneity of the techniques used to assess such
associations and the way in which they are reported. There
was also wide variation in the measurement of outcome
and the use of validated measures would improve
interpretability and comparability of future studies’’ [57]
Osteosarcoma ‘‘93 papers were studied in depth…. Only
7 papers were of sufficient quality to analyze.… Because of
heterogeneity of the studies, pooling results is hardly
possible. There is a need for standardization of studies and
report’’ [58]
Peptic ulcer perforation ‘‘Fifty prognostic studies with
37 prognostic factors comprising a total of 29,782 patients
were included in the review. The overall methodological
quality was acceptable, yet only two-thirds of the studies
provided confounder adjusted estimate’’ [59]
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whether glucose is a prognostic factor of unfavourable six month
outcome (defined by a Glasgow Outcome Score of 1, 2 or 3) in
patients with traumatic brain injury. The meta-analysis in (A)
confirms that glucose is a prognostic factor, as the odds of the
outcome increase as glucose levels increase (odds ratio .1).
Further, the meta-analysis in (B) shows that glucose is an
‘independent’ prognostic factor, as its prognostic value largely
remains even after adjusting for the other prognostic factors of age,
motor score and pupillary reactivity.
(DOC)
Table S1 Recommendations of PROGRESS (PROGno-
sis RESearch Strategy).
(DOC)
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